Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report
| Autor: | Teruhiko Tsuru, Susumu Kageyama, Keiji Tomita, Ryo Fujiwara, Takahiro Isono, Tetsuya Yoshida, Mitsuhiro Narita, Eiki Hanada, Akihiro Kawauchi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Pathology
medicine.medical_specialty Published online: August 2015 medicine.drug_class medicine.medical_treatment Urology Docetaxel urologic and male genital diseases lcsh:RC254-282 Lesion Prostate medicine Chemotherapy Ductal adenocarcinoma Prostatic ductal adenocarcinoma medicine.diagnostic_test business.industry Androgen Transurethral biopsy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Blockade medicine.anatomical_structure Oncology medicine.symptom business medicine.drug |
| Zdroj: | Case Reports in Oncology, Vol 8, Iss 2, Pp 339-344 (2015) Case Reports in Oncology |
| ISSN: | 1662-6575 |
| Popis: | A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumontanum was found by cystourethroscopy. Serum prostate-specific antigen (PSA) was 3.246 ng/ml. A transurethral biopsy specimen was most suggestive of a primary urothelial carcinoma of the prostate, for which a radical cystoprostatectomy was performed. The final pathology was prostatic ductal adenocarcinoma with very focal acinar features (Gleason score 5 + 4 = 9, pT3bN0M0). Local recurrence and pelvic bone metastases developed 17 months later, and his PSA rose to 10.806 ng/ml. He was treated with combined androgen blockade and radiation. Two years later, the lesion showed progressive growth. Treatment followed with docetaxel (70 mg/m2 every 3 weeks) and prednisolone 5 mg twice daily. After 10 cycles of chemotherapy, all lesions disappeared and PSA decreased to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |